Business Wire

  1. Horizon Therapeutics plc Announces U.S. FDA Acceptance Of Its New Drug Application To Make PROCYSBI (Cysteamine Bitartrate) Available As Oral Granules In Packets

    Horizon Therapeutics plc announced recently that the U.S. Food and Drug Administration (FDA) has accepted Horizon’s New Drug Application (NDA) for PROCYSBI (Cysteamine Bitartrate) Delayed-Release Oral Granules in Packets

  2. Gotham Therapeutics And Mercachem Announce Progress In Compound Library Development Tailored For Epitranscriptomic Drug Discovery

    Gotham Therapeutics , a biotechnology company developing a novel drug class targeting RNA-modifying proteins, and Mercachem, the leading European contract research organization, recently announced the generation of a high-quality compound library tailor-made for accelerated hit generation and hit-to-lead expansion against large parts of the epitranscriptomic target space

  3. Arrowhead Pharmaceuticals Receives Orphan Drug Designation For ARO-ANG3

    Arrowhead Pharmaceuticals Inc. recently announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ARO-ANG3 for the treatment of homozygous familial hypercholesterolemia (HoFH)

  4. Gilead And Galapagos Enter Into Transformative Research And Development Collaboration

    Gilead Sciences, Inc. and Galapagos NV recently announced that they have entered into a 10-year global research and development collaboration. 

  5. Research Collaboration Between U-M And Atomwise To Accelerate Drug Discovery Using Innovative Artificial Intelligence Approach

    From making pain management safer and more effective to identifying inhibitors for a fibrosis target protein and more, researchers from Michigan Medicine, as well as the University of Michigan College of Pharmacy and U-M Life Sciences Institute, are looking to advance their projects through Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program, which uses AI-powered screening technology employed by large pharmaceutical companies

  6. Abveris And Harbour Antibodies H2L2 BV Announce Technology Co-Offering Agreement For Fully Human Antibody Discovery

    Abveris, Inc., a global leader in contract research antibody discovery, and Harbour Antibodies H2L2 BV, a wholly-owned subsidiary of Harbour BioMed, recently announced a partnership to offer fully-human antibody discovery service that combines Abveris’ antibody discovery services with the Harbour H2L2 human transgenic mouse platform

  7. Puma Biotechnology Submits A Supplemental New Drug Application To U.S. FDA For Neratinib To Treat HER2-Positive Metastatic Breast Cancer

    Puma Biotechnology, Inc., a biopharmaceutical company, has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for neratinib in combination with capecitabine for the treatment of patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments (third-line disease)

  8. LifeMax Receives Orphan Drug Designation From The United States Food & Drug Administration For LM-030 For The Treatment Of Netherton Syndrome

    LifeMax Laboratories, Inc. (“LifeMax”), a private company focused on treating rare diseases with few or no therapeutic options, recently announced that the Food & Drug Administration (FDA) granted orphan drug designation to LM-030, an investigational therapy licensed from Novartis and ready to enter into pivotal clinical trials for the treatment of Netherton Syndrome

  9. PeptiDream Announces New Peptide Drug Conjugate (‘PDC’) Collaboration Agreement With Novartis

    PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced recently a new Peptide Drug Conjugate “PDC” collaboration agreement with Swiss-based Novartis (“Novartis”)

  10. Gilead And Carna Biosciences Announce Research And Development Collaboration To Develop Novel Immuno-Oncology Therapies

    Gilead Sciences, Inc. and Carna Biosciences Inc recently announced that the companies have entered into a research and development collaboration to develop and commercialize small molecule compounds in immuno-oncology and to access Carna’s proprietary lipid kinase drug discovery platform